Sign up to save your podcasts
Or
Share Critical Timing: Hikma’s Billion-Dollar U.S. Investment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Critical Timing: Hikma’s Billion-Dollar U.S. Investment
Generics, which make up approximately 90% of prescription volume in the U.S., are produced primarily in India as Hikma looks to onshore production of these critical drugs.
Greg Slabodkin
Read by Brittany Duncan
https://www.pharmamanufacturing.com/all-articles/article/55302441/hikmas-planned-1b-us-investment-comes-at-critical-time-for-generic-medicines-supply
View all episodes
By Pharma Manufacturing
5
66 ratings
Generics, which make up approximately 90% of prescription volume in the U.S., are produced primarily in India as Hikma looks to onshore production of these critical drugs.
Greg Slabodkin
Read by Brittany Duncan
https://www.pharmamanufacturing.com/all-articles/article/55302441/hikmas-planned-1b-us-investment-comes-at-critical-time-for-generic-medicines-supply
More shows like Off Script: A Pharma Manufacturing Podcast
View all
TED Radio Hour
22,036 Listeners
Planet Money
30,877 Listeners
The McKinsey Podcast
382 Listeners
Odd Lots
2,000 Listeners
Pivot
9,702 Listeners
The Daily
113,164 Listeners
Up First from NPR
57,032 Listeners
The Readout Loud
338 Listeners
The Prof G Pod with Scott Galloway
5,627 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,273 Listeners
BioCentury This Week
35 Listeners
Podnosis
4 Listeners